These downloadable slides by Dr. Thomas E. Keane, MD are on the topic of the mechanisms of action of ADT treatment for men with prostate cancer. These slides were presented at a satellite symposium presented in conjunction with the AUA Annual Meeting held on Sunday, May 14, 2017 entitled “Navigating the Adverse Effects of ADT: Improving Patient Outcomes.
About The Author
In June 2002, Dr. Thomas Keane, a surgical urologic oncologist and nationally recognized researcher with previous appointments at Emory University and Grady Memorial Hospital in Atlanta, accepted the position of Chairman of Urology at MUSC. Dr. Keane obtained his medical degree in Ireland and completed 7 years of general surgery before obtaining a research fellowship at Duke University which led to a urologic residency. He is currently a Professor of Urology and holds the Brockmann Chair in Urologic Oncology. An avid researcher, he has served as principal investigator/co-investigator on more than 20 major clinical/pre-clinical studies. His work focuses on innovative concepts in translational research, including utilizing human tumor xenografts to investigate new therapies as they relate to GU malignancies with particular reference to cytotoxic agents, sphingolipids, and boron-containing compounds. He holds a number of U.S. patents. Dr. Keane has published over 100 articles peer-reviewed in such journals as The Journal of Urology, Journal of Clinical Investigation, and Cancer Research. He provides editorial services to numerous urology journals and is coeditor of the text Glenn’s Urologic Surgery. Dr. Keane has chaired the renal section of the Eastern Cooperative Oncology Group and is an accomplished speaker, having delivered many presentations to professional societies and symposia throughout the United States and abroad.
Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?